retatrutide fda approval timeline 2025 Status 2026: Everything We Know So Far Retatrutide produces up to 30.3%
Description
GLP-1s and exercise don't have to feel overwhelming
GLP-1 receptor agonists like Ozempic may pose risks for patients with ulcerative colitis
What I'm watching: The Alzheimer's Association listed GLP-1 research as a top 10 development to watch in 2026
I dreaded eating and not eating alike. Plus-I had to eat bland starchy food to not be sick so I put the weight back on
Semaglutide was associated with a lower risk of suicidal thoughts than other anti-obesity and anti-diabetes drugs.
My research notes and experience trialling microdoses of Tirzepatide with mast cell activation syndrome, EDS & a spinal CSF leak.
